The phase 2 clinical trial of Verrica’s peptide-based immunotherapy for basal cell carcinoma has enrolled and dosed its final patient. VP-315, an oncolytic peptide, is injected directly into tumors to induce immunogenic cell death. The trial includes 80 patients with biopsy-proven BCC. Verrica’s VP-315 program aims to provide an alternative to surgery for BCC treatment, targeting the delivery of an oncolytic peptide to stimulate the patient’s immune system and destroy cancer cells. Data from the phase 2 clinical trial will be shared later this year.
Source link
Verrica completes dosing in basal cell carcinoma immunotherapy trial
